Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis

PURPOSE: EGFR pathway inhibition may promote anti–programmed cell death protein 1 (PD-1) responses in preclinical models, but how EGFR inhibition affects tumor antigen presentation during anti–PD-1 monotherapy in humans remain unknown. We hypothesized that afatinib, an irreversible EGFR tyrosine kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kao, Hsiang-Fong, Liao, Bin-Chi, Huang, Yen-Lin, Huang, Huai-Cheng, Chen, Chun-Nan, Chen, Tseng-Cheng, Hong, Yuan-Jing, Chan, Ching-Yi, Chia, Jean-San, Hong, Ruey-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306266/
https://www.ncbi.nlm.nih.gov/pubmed/35046059
http://dx.doi.org/10.1158/1078-0432.CCR-21-3025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306266/
https://www.ncbi.nlm.nih.gov/pubmed/35046059
http://dx.doi.org/10.1158/1078-0432.CCR-21-3025

Ejemplares similares